GFAP and myeloid sarcoma: Unbiased mass spectrometry-based approaches have identified panels of proteins that differentiate NMOSD from MS and healthy controls, including elevated levels of glial fibrillary acidic protein (GFAP), a specific marker of astrocyte injury, and other proteins related to complement activation and innate immunity (83–85).